Hartwich G, Brandt W, Petzoldt R
Med Klin. 1975 Apr 4;70(14):622-5.
In 67 patients with acute leukemia 76 treatment-series were performed which were analyzed to evaluate whether chemotherapy has brought some progress during the past years. With 67 sufficient treatments a total of 26 remissions were achieved. VIDaP-scheme with 43 p.c. and cytosinarabinosid with 46 p.c. were significantly superior to the older scheme methotrexat-purinethol-prednisone with only 29 p.c. remissions. A remarkable deterioration of prognosis with increasing age rises the question whether treatment with cytotoxic drugs should be tried in patients more than 60 years old. Remission rate in patients below 20 was especially high with 71 p.c. so that the well-known good prognosis of juvenile leukemia can be extended with some limitations until age 20.
对67例急性白血病患者进行了76个疗程的治疗，并对这些疗程进行分析，以评估化疗在过去几年中是否取得了一些进展。在67个充分的疗程中，共实现了26次缓解。采用VIDaP方案的缓解率为43%，采用阿糖胞苷的缓解率为46%，均显著优于甲氨蝶呤-巯嘌呤-泼尼松这一旧方案，后者的缓解率仅为29%。随着年龄增长预后显著恶化，这引发了一个问题，即对于60岁以上的患者是否应尝试使用细胞毒性药物进行治疗。20岁以下患者的缓解率特别高，为71%，因此青少年白血病众所周知的良好预后在一定程度上可以延伸至20岁。
